Physician profile
Paul E Finley
NPI 1073517660
$2,778.35
in general payments reported to CMS, 2019-2025
23 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $30.25 · 2021: $108 · 2022: $90.75 · 2023: $453 · 2024: $1,422 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,200 · Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,200.00 |
| Food and Beverage | $1,123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,264.67 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Regeneron Healthcare Solutions, INC. | $443.89 | 2019-2024 | Eylea Hd, Eylea |
| Alcon Vision LLC | $156.66 | 2019-2025 | Clareon |
| Abbvie INC. | $154.07 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $142.95 | 2019-2025 | Tecnis Iol, Veritas Vision System, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $93.92 | 2022-2024 | Cequa |
| Thea Pharma INC. | $67.19 | 2023-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $50.57 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $46.73 | 2024-2025 | Miebo, Xiidra |
| Amgen INC. | $45.37 | 2024 | Tepezza |
| Kala Pharmaceuticals, INC. | $42.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $41.96 | 2019 | |
| Aerie Pharmaceuticals, INC. | $41.55 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $37.94 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $19.85 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $19.76 | 2023 | |
| Omeros Corporation | $18.61 | 2019 | |
| Horizon Therapeutics Plc | $17.21 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $16.86 | 2025 | Ultomiris |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.50 | 2021 | |
| Allergan, INC. | $15.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.31 | 2021 | |
| Iridex Corporation | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Finley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.